BMD and MND Sign Research Agreement Covering Infectious Disease Multiplex Assays
News May 05, 2006
BioMedical Diagnostics (BMD) has announced a collaboration and research project with Modules for Novel Diagnostics Ltd. (MND), an Israel-based company specialized in specific viral and bacterial detection.
This research agreement covers different assays or tests for the diagnosis of infectious diseases.
This collaboration project could potentially lead to the development of tests using FIDIS™ technology and the CARIS™ sample preparation system.
MND's technology directly measures the presence of live viruses and bacteria in body fluids by detecting the specific enzymatic activity of microorganisms during replication.
The activity of these enzymes on specific substrates triggers an emission of fluorescence. This makes possible differential diagnosis of not only of viral families but also of subtypes.
Sophisticated bio-informatics analysis used by MND has enabled the company to design specific substrate sequences, which make the tests accurate.
The technology can be applied in many fields, including the diagnosis and identification of avian flu and its mutations.
The two companies have signed a research agreement the objective of which is to demonstrate the compatibility of MND and FIDIS technology.
It should therefore lead to the design of diagnostic kits able to be used on the automated CARIS-FIDIS platform.
FIDIS is a flow cytometer based on optical sorting and fluorescent measurement of colored beads.
The FIDIS system can be connected to a Laboratory Information System, as well as to CARIS™, the sample preparation system that automates the different analytical steps.
This multiparametric solution is suitable for any size of laboratory, given the variety of products that can be used on the same instrumentation systems. It caters for the diagnosis of both autoimmune and infectious diseases.
Moreover, this automation system is designed to offer users a safe environment for analyses and gives results in a shorter time than traditional methods.
"The research agreement between MND and bmd will allow the two companies to offer better, faster and less costly methods of bacterial and viral analysis than those currently available," said Dr Patrick G. Poty, bmd's CEO.
"BMD's ability to market 10-marker automated panels for autoimmune diseases augurs well for a mutually beneficial collaboration, and we have no doubt that we will be able to bring to market Multiplex tests that as yet do not exist for infectious diseases," declared Dr Dorit Arad, President of MND.